News

Biomedical people have their own title review "stage"

  • Categories:Media
  • Author:
  • Origin:
  • Time of issue:2022-03-28
  • Views:0

(Summary description) As a benchmark to measure the ability and level of professional and technical talents, the title is a ladder and a channel for professional and technical talents' career development, and assumes an important function to guide and motivate professional and technical talents. For high-end talents, especially many returnee innovation and entrepreneurial talents, the title is not only related to the declaration of various scientific research funds, but also an "endorsement" of their professional ability. Recently, Suzhou Daily published a report of "Pilot Field for Biomedical Title Review", let's take a look at the "stage" of biomedical talents' own title review.

Biomedical people have their own title review "stage"

(Summary description) As a benchmark to measure the ability and level of professional and technical talents, the title is a ladder and a channel for professional and technical talents' career development, and assumes an important function to guide and motivate professional and technical talents. For high-end talents, especially many returnee innovation and entrepreneurial talents, the title is not only related to the declaration of various scientific research funds, but also an "endorsement" of their professional ability. Recently, Suzhou Daily published a report of "Pilot Field for Biomedical Title Review", let's take a look at the "stage" of biomedical talents' own title review.

  • Categories:Media
  • Author:
  • Origin:
  • Time of issue:2022-03-28
  • Views:0

 As a benchmark to measure the ability and level of professional and technical talents, the title is a ladder and a channel for professional and technical talents' career development, and assumes an important function to guide and motivate professional and technical talents. For high-end talents, especially many returnee innovation and entrepreneurial talents, the title is not only related to the declaration of various scientific research funds, but also an "endorsement" of their professional ability. Recently, Suzhou Daily published a report of "Pilot Field for Biomedical Title Review", let's take a look at the "stage" of biomedical talents' own title review.

  At the end of last year, Suzhou Industrial Park took the lead in launching the pilot biomedical engineering title review in China. With the release of the first batch of the employed list, this pilot initiative has achieved a number of innovations: biomedical engineering has a place in the domestic professional title sequence for the first time, the "Jiangsu Province Biomedical Engineering Professional and Technical Qualification Conditions" has been implemented for the first time, the returnee leaders can directly "jump" to apply for senior titles, and the industry has hired the first evaluation chairman represented by entrepreneurs. In the first batch of the evaluation list, there are 16 people on the list, 12 of whom were awarded senior titles in biomedical engineering.

  A major change: whether it is talent by the enterprise to say

  In the past, the judges of the title evaluation often came from colleges and universities, and the evaluation criteria also put more emphasis on education, papers, the number of patents held and other indicators. However, in this round of biomedical engineering assessment in the park, the characteristics of "academy" are changed, and whether it is talent or not is often decided by enterprises.

  As one of the chairman members of the Suzhou Biomedical Engineering Senior Professional Technical Qualification Review Committee, Yu Qiang, founder and CEO of CGeneTech (Suzhou, China) Co., Ltd. "This time, the title review introduced a percentage-based tool, including evaluation conditions such as papers and performance innovation results that meet the growth rules and technical characteristics of talents in the field of biopharmaceuticals, while including the evaluation of innovation research and development and other performance as criteria, focusing on the quality of research results." Yu Qiang said that he comes from the corporate world, and the evaluation will look at the applicants' academic qualifications, but focus more on judging their ability to apply their knowledge to real-world problems, which brings more flexible and practical judgment criteria. "For talents with high professional and technical level, the review will relatively dilute the requirement of the number of papers, highlighting the evaluation of professional and technical personnel job performance by the employer, forming a practical evaluation of talent orientation." Yu Qiang said.

  Industrial development as the guide to assess the professional ability of talent, the introduction of the business community judges is a major innovation this time. According to Jiang Weidong, deputy director of Human Resources and Social Security Bureau of the park, the park has not only set up a biomedical title evaluation expert pool with seven people as director members, but also hired a 70-member team of judges. Most of these judges come from enterprises and industries in order to play the main role of enterprises in talent assessment as much as possible. "We assess the title requirements to the main unit, open the port to enterprises, through the enterprise gatekeeper, so that enterprises in the evaluation of the combination of use of talent to retain and use the talent." Jiang Weidong said.

  In addition, the park also innovated the assessment method, pioneered the participation of industry associations in title assessment, and the biomedical industry promotion association specifically undertakes title assessment. At the end of last year, the comprehensive service center of biomedical industry in Suzhou Biomedical Industry Park was opened. Relying on this position, the Biomedical Industry Promotion Association moved the service port forward and opened a special window in the comprehensive service center, which was served by a dedicated person and effectively improved the review efficiency.

  In fact, "by me" will not only gradually form the main evaluation system to the employer, will also bring a lot of "surprise". Yu Qiang told reporters that he was successfully evaluated some years ago as a senior title of chemical engineering, smoothly in the College of Pharmacy of Soochow University as an industrial professor. This "cross-border" status makes it easier for him to understand the direction of the school's research and the details of talent training. "If enterprises can select and evaluate a group of talents with senior titles from a practical point of view, and establish contact with universities or institutes through them, they may be able to find the 'interface' of industry-university-research docking more precisely." In his opinion, with these talent "bridges", schools and enterprises can jointly develop a training system suitable for industrial talents in the future, and jointly create the "strongest magnetic field" for attracting and gathering talents.

1

 

About CGeneTech

  Founded in 2010 in Suzhou Industrial Park, CGeneTech (Suzhou, China) Co., Ltd. has a core team with decades of international experience in the full life cycle of pharmaceuticals, and is dedicated to the development and industrialization of small molecule innovative drugs for breakthrough therapeutics. With its integrated drug discovery technology platform and diversified business vision, the company has built a rich pipeline of Class 1 innovative drugs covering various disease areas such as hypoglycemia and anticancer. Among them, Cetagliptin phosphate is expected to fill the gap of original DPP-4 inhibitors in China, while the first generic drug for the treatment of rare disease multiple sclerosis, Teriflunomide tablets, has also been approved for marketing. In the future, the company will focus on the unmet clinical needs in China and around the world to develop innovative drugs with high patient accessibility and better efficacy to benefit patients worldwide.

 
Shengshi

Shengshi Taike has been awarded the "Double Yellow Egg" of Jiangsu Province's innovation and entrepreneurship talents

Jiangxiang is near Xiaoman, with warm air and moving grasshoppers. Recently, the selection results of Jiangsu Province's "Double Innovation Plan" for 2024 have been officially announced. Shengshi Taike's talent team has won the "Double Yellow Egg" award: the core team led by Dr. Wang Tong, Chief Scientific Officer, has been successfully selected as the "Double Innovation Team" in Jiangsu Province in 2024, and is the only "Innovation Team" in the field of biomedicine in Suzhou; Dr. Zhao Jiahong, Chief Medical Officer, has been successfully selected as a "Double Innovation Talent" in Jiangsu Province in 2024. The "Double Innovation Plan" in Jiangsu Province mainly focuses on introducing and funding scarce talents in the "high-precision and cutting-edge" and "bottleneck" fields, supporting the development of new technologies in key areas, and is an important brand project for talent work in Jiangsu Province. This plan focuses on the key industries prioritized for development in Jiangsu Province, playing an important role in enhancing independent innovation capabilities, promoting industrial structure optimization and upgrading, and driving rapid economic development. Dr. Wang Tong was just awarded the title of "Double Innovation Talent" in Jiangsu Province last year, and this time he led the company's core team to win the honor of "Double Innovation Team" in Jiangsu Province, fully reflecting the continuous innovation ability of the company's talent team. Dr. Wang Tong, as the Chief Scientific Officer of Shengshi Taike, has over 20 years of experience in the full chain drug research and management of top pharmaceutical companies and research institutes in the United States. He is a strategic scientist who can break through key technologies, drive emerging disciplines, and promote the new drug industry. Since joining Shengshi Taike, I have been awarded the title of leading technology talent at all levels, bringing innovative thinking and advanced technological means to the company. I have integrated and formed a complete new drug development and industrialization platform, leading the company's R&D team to accelerate the development of the new drug product pipeline. One of the core product pipelines, the hypoglycemic drug sengliptin, has been launched for sale. Dr. Zhao Jiahong, a core member of the "Double Creation Team", was also awarded the honor of "Double Creation Talent" in Jiangsu Province this time. Dr. Zhao Jiahong, as the Chief Medical Officer of Shengshi Taike, has over 20 years of experience in drug clinical trials and team management, and is an external expert of CDE; Has rich practical experience in medical affairs and early drug development, clinical development strategies, and international multicenter clinical trials, and has led and participated in over 600 clinical projects; I also have some experience in post market re evaluation of drugs. Since joining Shengshi Taike, I have been fully responsible for the company's new drug clinical development strategy and pathway, as well as post market expansion research and other important tasks. Among the core members of the "Double Creation Team", Dr. Lu Qin graduated from Fudan University with a major in Medical Systems Biology and holds the associate senior professional title. She has achieved fruitful research results in the field of biology, published multiple high-quality papers, obtained nearly 10 authorized invention patents, led the company's biology team to complete multiple project research tasks, and won multiple honors such as leading the park. Dr. Ouyang Zhenwu graduated from the Organic Chemistry Department of the Chinese Academy of Sciences. He has demonstrated outstanding academic and professional achievements in the field of pharmaceutical chemistry. He has published six high-quality papers in internationally renowned chemical journals, demonstrating his profound skills in chemical synthesis and drug design. Since joining the company, Dr. Ouyang has repeatedly used "innovative synthesis methods" to simplify the synthesis route, which not only significantly improves the efficiency of new drug screening, but also saves costs for the company in new drug development. Shengshi Taike, composed of these innovative talent teams, is a biotechnology company in the commercial stage. The core team has decades of experience in the entire lifecycle of international drugs and is committed to the research and industrialization of high-quality and differentiated small molecule innovative drugs. The company has built a rich pipeline of innovative drugs covering hypoglycemic, anticancer, and autoimmune diseases through an integrated drug research and development technology platform and diversified business perspectives.
2025-05-22
Media

Media Attention | Yu Qiang, an "unsmart" entrepreneur, and his new diabetes drug Sengliptin

Qiang Yu, the founder and CEO of CGeneTech, a doctor of chemistry from Peking University, founded a biotechnology company in the United States at the beginning of this century, and later returned to China to found CGeneTech and developed a new type 2 diabetes drug, a new generation of DPP-4 inhibitor senpaglitin, which has now been approved for marketing.
2025-04-16

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO